Pulmonary Hypertension: Therapeutic Targets Within the Serotonin System

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2008 Jun 10

PMID 18536742

Citations 41

Authors

Y Dempsie

M R MacLean

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is characterized by a sustained and progressive elevation in pulmonary arterial pressure and pulmonary vascular remodelling leading to right heart failure and death. Prognosis is poor and novel therapeutic approaches are needed. The serotonin hypothesis of PAH originated in the 1960s after an outbreak of the disease was reported among patients taking the anorexigenic drugs aminorex and fenfluramine. These are indirect serotonergic agonists and serotonin transporter substrates. Since then many advances have been made in our understanding of the role of serotonin in the pathobiology of PAH. The rate-limiting enzyme in the synthesis of serotonin is tryptophan hydroxylase (Tph). Serotonin is synthesized, through Tph1, in the endothelial cells of the pulmonary artery and can then act on underlying pulmonary arterial smooth muscle cells and pulmonary arterial fibroblasts in a paracrine fashion causing constriction and remodelling. These effects of serotonin can be mediated through both the serotonin transporter and serotonin receptors. This review will discuss our current understanding of 'the serotonin hypothesis' of PAH and highlight possible therapeutic targets within the serotonin system.

Citing Articles

5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function.

Walker M, Bloodworth J, Kountz T, McCarty S, Green J, Ferrie R Front Allergy. 2024; 5:1385168.

PMID: 38845678 PMC: 11153829. DOI: 10.3389/falgy.2024.1385168.

Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension.

Charoenpong P, Hall N, Keller C, Kumar Ram A, Murnane K, Goeders N Chest. 2024; 165(6):1518-1533.

PMID: 38211700 PMC: 11177101. DOI: 10.1016/j.chest.2024.01.014.

Recent Advances in the Treatment of Pulmonary Arterial Hypertension.

Otani N, Tomoe T, Kawabe A, Sugiyama T, Horie Y, Sugimura H Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297387 PMC: 9609229. DOI: 10.3390/ph15101277.

Investigation of Genes and Proteins Expression Associating Serotonin Signaling Pathway in Lung and Pulmonary Artery Tissues of Dogs with Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease: The Preliminary Study.

Tangmahakul N, Sakarin S, Techangamsuwan S, Rungsipipat A, Surachetpong S Vet Sci. 2022; 9(10).

PMID: 36288144 PMC: 9612059. DOI: 10.3390/vetsci9100530.

Persistent Pulmonary Hypertension: A Look Into the Future Therapy.

Soni M, Joshi P, Patel S, Shreya D, Zamora D, Patel G Cureus. 2022; 13(12):e20377.

PMID: 35036210 PMC: 8753505. DOI: 10.7759/cureus.20377.

References

Fagan K, Oka M, Bauer N, Gebb S, Ivy D, Morris K . Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004; 287(4):L656-64. DOI: 10.1152/ajplung.00090.2003. View

Yang X, Long L, Southwood M, Rudarakanchana N, Upton P, Jeffery T . Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005; 96(10):1053-63. DOI: 10.1161/01.RES.0000166926.54293.68. View

Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y . Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2003; 94(3):385-93. DOI: 10.1161/01.RES.0000111804.34509.94. View

Eddahibi S, Hanoun N, Lanfumey L, Lesch K, Raffestin B, Hamon M . Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000; 105(11):1555-62. PMC: 300850. DOI: 10.1172/JCI8678. View

Sankelo M, Flanagan J, Machado R, Harrison R, Rudarakanchana N, Morrell N . BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension. Hum Mutat. 2005; 26(2):119-24. DOI: 10.1002/humu.20200. View

Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J . Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther. 2005; 313(2):539-48. DOI: 10.1124/jpet.104.081182. View

Rothman R, Baumann M . Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther. 2002; 95(1):73-88. DOI: 10.1016/s0163-7258(02)00234-6. View

Hyvelin J, Howell K, Nichol A, Costello C, Preston R, McLoughlin P . Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res. 2005; 97(2):185-91. DOI: 10.1161/01.RES.0000174287.17953.83. View

Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N . Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J. 2006; 70(2):174-8. DOI: 10.1253/circj.70.174. View

10.

Lee S, Wang W, Finlay G, Fanburg B . Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol. 1999; 277(2):L282-91. DOI: 10.1152/ajplung.1999.277.2.L282. View

11.

MacLean M . Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?. Trends Pharmacol Sci. 1999; 20(12):490-5. DOI: 10.1016/s0165-6147(99)01389-9. View

12.

Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View

13.

Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S . Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274(5292):1527-31. DOI: 10.1126/science.274.5292.1527. View

14.

Lawrie A, Spiekerkoetter E, Martinez E, Ambartsumian N, Sheward W, MacLean M . Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005; 97(3):227-35. DOI: 10.1161/01.RES.0000176025.57706.1e. View

15.

MacLean M, Deuchar G, Hicks M, Morecroft I, Shen S, Sheward J . Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004; 109(17):2150-5. DOI: 10.1161/01.CIR.0000127375.56172.92. View

16.

Caccia S, Anelli M, Ferrarese A, Fracasso C, Garattini S . The role of d-norfenfluramine in the indole-depleting effect of d-fenfluramine in the rat. Eur J Pharmacol. 1993; 233(1):71-7. DOI: 10.1016/0014-2999(93)90350-q. View

17.

Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur A, Saurini F . Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2007; 293(4):L1045-52. DOI: 10.1152/ajplung.00082.2007. View

18.

Rochefort G, Lemaire M, Eder V, Hanton G, Hyvelin J, Bonnet P . Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension. Eur J Pharmacol. 2006; 550(1-3):149-54. DOI: 10.1016/j.ejphar.2006.08.050. View

19.

Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D . Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005; 111(21):2812-9. DOI: 10.1161/CIRCULATIONAHA.104.524926. View

20.

Newman J, Trembath R, Morse J, Grunig E, Loyd J, Adnot S . Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004; 43(12 Suppl S):33S-39S. DOI: 10.1016/j.jacc.2004.02.028. View